Osiris
Therapeutics OSIR announced today that, on November 27, 2013, the
Centers for Medicare and Medicaid Services (CMS) released their proposed
ruling for the reimbursement of skin substitutes in the hospital
outpatient setting. CMS decided to package the reimbursement for
products used in advanced wound care with the related surgical procedure
into a two-tier system.
The proposed ruling means that the current payment methodology for Grafix®
will not immediately be impacted by the changes described in the
proposed ruling. Grafix will maintain its current transitional
pass-through status and that
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in